Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

DNA methylation markers to predict treatment success of biologicals in Crohn’s disease.

Descrizione del progetto

DE EN ES FR IT PL

Biomarcatori dell’esito del trattamento per le malattie immunitarie

In molte malattie mediate dal sistema immunitario, come il morbo di Crohn e l’artrite reumatoide, è necessario sopprimere il sistema immunitario. Ed è qui che entra in scena la terapia biologica, come la somministrazione di anticorpi terapeutici che prendono di mira le proteine infiammatorie o bloccano l’attività/il traffico delle cellule immunitarie. Tuttavia, il successo del trattamento è variabile e non ci sono biomarcatori in grado di prevedere la risposta clinica, il che produce sofferenze inutili per i pazienti e costi sanitari elevati. Il progetto METHYLOMIC, finanziato dall’UE, si concentra sull’epigenetica come mezzo per prevedere l’esito delle terapie biologiche. Un gruppo di ricerca introdurrà e convaliderà biomarcatori della metilazione del DNA in qualità di predittori precisi della risposta alla terapia.

Obiettivo

Monoclonal antibodies have become a mainstay of therapy in common immune-mediated diseases (IMID) including Crohn’s disease (CD), rheumatoid arthritis (RA), and psoriasis (PsO). Current therapeutics include antibodies (“biologicals”) targeting inflammatory proteins such as Tumor Necrosis Factor (adalimumab), leukocyte trafficking (vedolizumab), or IL-12/IL-23 (ustekinumab). At present however, it cannot be predicted which biological will be effective in an individual patient, with only <40% of patients showing primary response to any given therapeutic. Treatment failure is associated with disease complications, and increased health care costs.. Hence the overwhelming need for predictive biomarkers to guide personalised medicine in IMID is evident. No biomarker to target therapy is validated in clinical practice.

In METHYLOMIC, we build on multiple previous cohort studies in which we confirmed epigenetic biomarkers (specifically DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD. Specifically, we discovered and validated differential DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for 3 approved biologicals in CD. Through the use of machine learning algorithms, treatment response could be predicted with up to 93% accuracy for each biological for CD, and RA.

METHYLOMICS is committed to bringing personalised treatment-selection in CD and other IMID to clinical practice. We have teamed up clinical, epigenetic, and DNA diagnostics experts, patient organisations, and companies across Europe, for further validation studies, develop a marketable rapid targeted methylation assay that we than validate in a unique prospective randomised clinical trial for CD. Efficiency and cost-effectiveness is assessed in great detail and regulatory approval is guided by experts to assure delivery of the first epigenetic kit personalised treatment of CD.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

HORIZON-HLTH-2022-TOOL-11

Vedi altri progetti per questo bando

Meccanismo di finanziamento

HORIZON-RIA - HORIZON Research and Innovation Actions

Coordinatore

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Contribution nette de l'UE
€ 2 115 730,25
Indirizzo
MEIBERGDREEF 15
1105AZ Amsterdam
Paesi Bassi

Mostra sulla mappa
Regione
West-Nederland Noord-Holland Groot-Amsterdam
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 2 115 730,25

Partecipanti (13)

Partner (4)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 24 Maggio 2023

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/101095449/it

European Union, 2024